Gastric Carcinoma Clinical Trial
Official title:
A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
This multicenter, randomized study will evaluate the efficacy and safety of apatinib compared to docetaxel treatment in patients with advanced gastric cancer. At the start of the trial, patients will be randomized to one treatment arm: Arm A: apatinib 850mg qd every 3 weeks; Arm B: docetaxel 60mg/m2 every 3 weeks. Tumor assessment will be done every 8 weeks according to RECIST 1.1. The primary endpoint is progression free survival (PFS).
Status | Recruiting |
Enrollment | 66 |
Est. completion date | March 2017 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patients, aged =18 years; - Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC) , including adenocarcinoma of the gastroesophageal junction ; - At least one measurable and evaluable disease based on response evaluation criteria in solid tumors (RECIST v1.1); - Patients must have received one prior chemotherapy regimen for AGC;First-line therapy must have included a combination of at least a platinum-based treatment given concurrently, and must have experienced disease progression during or after first-line therapy for their disease; - Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1; - Life expectancy of more than 3 months; - Duration from the last therapy is more than 6 weeks for nitroso or mitomycin, More than 4 weeks for other cytotoxic agents, operation or radiotherapy; - Adequate hepatic, renal, heart, and hematologic functions ( hemoglobin= 90g/L, platelets = 80 × 109/L, neutrophil =1.5 × 109/L, serum creatinine= 1.5mg/dl, total bilirubin =1.5 ×ULN, and serum transaminase=2.5×ULN); Exclusion Criteria: - Pregnant or lactating women; - History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix; - Prior chemotherapy regimen have included taxane (docetaxel or paclitaxel); Uncontrolled hypertension; - Intercurrence with one of the following: coronary artery disease, arrhythmia and heart failure; - Urine protein>grade 1; - Any factors that influence the usage of oral administration; - patients with a clear tendency of gastrointestinal bleeding; - Abnormal coagulation function(INR=1.5, APTT=1.5 ULN); - Abuse of alcohol or drugs; - Less than 4 weeks from the last clinical trial; - Prior treatment with antivascular endothelial growth factor or the other anti angiogenesis therapy; - Evidence of central nervous system(CNS) metastasis; - Disability of serious uncontrolled intercurrence infection. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Zhongshan Hospital Affiliated to Fudan University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Zhongshan Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | defined as the time from randomize to progression or death; RECIST guidelines were used to define all responses after patients had received every 8 weeks of therapy | Approximately 1 year | No |
Secondary | Overall survival (OS) | defined as the time from randomize to death | Approximately 3 years | No |
Secondary | Objective response rate (ORR) | defined as the rate of complete response and partial response according to RECIST guidelines. | Approximately 1 year | No |
Secondary | Disease control rate(DCR) | defined as the rate of complete response , partial response and stable disease according to RECIST guidelines. | Approximately 1 year | No |
Secondary | Quality of life(QoL) | as measured by the European Organization for Research and Treatment of Cancer questionnaire (EORTC QLQ C30) | Approximately 3 years | Yes |
Secondary | Safety (incidence of adverse events) | incidence of adverse events | Approximately 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04602026 -
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
|
N/A | |
Not yet recruiting |
NCT03599778 -
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00256321 -
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
|
Phase 2 | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Recruiting |
NCT02617134 -
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
|
Phase 1/Phase 2 | |
Recruiting |
NCT02317471 -
Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03735511 -
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
|
||
Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
Recruiting |
NCT05596188 -
Anxiety Before Non-cardiac Surgery in Adults
|
||
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT01348009 -
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT00639522 -
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
|
Phase 1 | |
Recruiting |
NCT05811546 -
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma
|
||
Recruiting |
NCT05229809 -
Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer
|
Phase 4 | |
Completed |
NCT00970138 -
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06408220 -
Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
|
N/A | |
Recruiting |
NCT04443036 -
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
|
N/A | |
Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 | |
Recruiting |
NCT02839954 -
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
|
Phase 1/Phase 2 |